Bayer HealthCare reports positive mCNV trial data

Bayer HealthCare has announced positive data from a phase III study showing the benefits its drug VEGF Trap-Eye could offer for myopic choroidal neovascularisation (mCNV) patients.

Results from the Myrror trial revealed that the drug was able to deliver a mean improvement in best-corrected visual acuity compared to placebo, while also being generally well-tolerated.

A total of 122 patients were involved in the study, with the primary endpoint being mean improvements after 24 weeks of treatment.

VEGF Trap-Eye is approved in a number of territories for the treatment of neovascular age-related macular degeneration (AMD) and macular oedema following central retinal vein occlusion, under the brand name Eylea.

Dr Kemal Malik, member of the Bayer HealthCare executive committee and head of global development, said: "We are pleased that the results of this study demonstrate that VEGF Trap-Eye provides a treatment option for these patients."

This comes after the UK's National Institute for Health and Care Excellence recommended the drug for use in the treatment of wet AMD for NHS patients earlier this week.